Abstract
Mutation of the p53 tumor suppressor gene is the most common genetic alteration in human cancer. p73, a member of the p53 family, has been found to exhibit activity similar to that of p53, including the ability to induce growth arrest and apoptosis. p53 and p73 have a high percentage of similarity at several domains, including the DNA binding domain. This domain in p53 is the location of missense mutations in many human cancers. Mutant p53, which cannot suppress cell proliferation, has been found to have a dominant-negative activity that inactivates wild-type p53. To determine the effects of mutant p53 on wild-type p73, we have established cell lines expressing both mutant p53 and wild-type p73 in a dual-inducible system. This system expresses mutant p53 in a tetracycline-repressible system and p73β in an ecdysone-inducible system in a p53-null lung carcinoma parental cell line. We have found that wild-type p73β, in the presence of mutant p53, retains the ability to transactivate p21 and suppresses cell growth through induction of both cell cycle arrest and apoptosis. In addition, in cell lines expressing wild-type p53 and wild-type p73β, we have found that these proteins cooperate to additively transactivate p21 and suppress cell proliferation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Almog N and Rotter V . (1997). Biochim. Biophys. Acta., 1333, F1–F27.
Brachmann RK, Vidal M and Boeke JD . (1996). Proc. Natl. Acad. Sci. USA, 93, 4091–4095.
Brunner HG, Hamel BC and Van Bokhoven H . (2002). J. Med. Genet., 39, 377–381.
Calhoun ES, McGovern RM, Janney CA, Cerhan JR, Iturria SJ, Smith DI, Gostout BS and Persing DH . (2002). Clin. Chem, 48, 1218–1224.
Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, Newbury-Ecob R, Hennekam RC, Van Buggenhout G, van Haeringen A, Woods CG, van Essen AJ, de Waal R, Vriend G, Haber DA, Yang A, McKeon F, Brunner HG and van Bokhoven H . (1999). Cell, 99, 143–153.
Chen X . (1999). Mol. Med. Today, 5, 387–392.
Chen X, Ko LJ, Jayaraman L and Prives C . (1996). Genes Dev., 10, 2438–2451.
Chen C and Okayama H . (1987). Mol. Cell. Biol., 7, 2745–2752.
Chene P . (1998). J. Mol. Biol., 281, 205–209.
Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD and Coffey RJ . (1997). Nat. Med., 3, 1233–1241.
Cho Y, Gorina S, Jeffrey PD and Pavletich NP . (1994). Science, 265, 346–355.
Dameron KM, Volpert OV, Tainsky MA and Bouck N . (1994). Science, 265, 1582–1584.
Davison TS, Vagner C, Kaghad M, Ayed A, Caput D and Arrowsmith CH . (1999). J. Biol. Chem., 274, 18709–18714.
De Laurenzi V, Rossi A, Terrinoni A, Barcaroli D, Levrero M, Costanzo A, Knight RA, Guerrieri P and and G . (2000). Biochem. Biophys. Res. Commun., 273, 342–346.
Di Como CJ, Gaiddon C and Prives C . (1999). Mol. Cell. Biol., 19, 1438–1449.
Dohn M, Jiang J and Chen X . (2001a). Oncogene, 20, 6503–6515.
Dohn M, Zhang S and Chen X . (2001b). Oncogene, 20, 3193–3205.
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B . (1993). Cell, 75, 817–825.
Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F and Jacks T . (2002). Nature, 416, 560–564.
Gaiddon C, Lokshin M, Ahn J, Zhang T and Prives C . (2001). Mol. Cell. Biol., 21, 1874–1887.
Gossen M and Bujard H . (1992). Proc. Natl. Acad. Sci. USA, 89, 5547–5551.
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW and Giaccia AJ . (1996). Nature, 379, 88–91.
Harvey DM and Caskey CT . (1998). Curr. Opin. Chem. Biol., 2, 512–518.
Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW and Vogelstein B . (1997). Mol. Cell, 1, 3–11.
Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R and Harris CC . (1994). Nucleic Acids Res., 22, 3551–3555.
Irwin MS and Kaelin WG . (2001). Cell Growth Differ., 12, 337–349.
Jost CA, Marin MC and Kaelin Jr WG . (1997). Nature, 389, 191–194.
Kaelin Jr WG . (1999). Oncogene, 18, 7701–7705.
Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F and Caput D . (1997). Cell, 90, 809–819.
Ko LJ and Prives C . (1996). Genes Dev., 10, 1054–1072.
Kovalev S, Marchenko N, Swendeman S, LaQuaglia M and Moll UM . (1998). Cell Growth Differ., 9, 897–903.
Levine AJ . (1997). Cell, 88, 323–331.
Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY and Melino G . (2000). J. Cell Sci., 113(Part 10), 1661–1670.
Lowe SW and Ruley HE . (1993). Genes Dev., 7, 535–545.
Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PW, Crook T and Kaelin Jr WG . (2000). Nat. Genet., 25, 47–54.
McGregor JM, Harwood CA, Brooks L, Fisher SA, Kelly DA, O'Nions J, Young AR, Surentheran T, Breuer J, Millard TP, Lewis CM, Leigh IM, Storey A and Crook T . (2002). J. Invest. Dermatol., 119, 84–90.
Mihara M, Nimura Y, Ichimiya S, Sakiyama S, Kajikawa S, Adachi W, Amano J and Nakagawara A . (1999). Br. J. Cancer, 79, 164–167.
Milner J and Medcalf EA . (1991). Cell, 65, 765–774.
Miyashita T and Reed JC . (1995). Cell, 80, 293–299.
Moll UM, Erster S and Zaika A . (2001). Biochim. Biophys. Acta, 1552, 47–59.
Morgenstern JP and Land H . (1990). Nucleic Acids Res., 18, 3587–3596.
Nelson WG and Kastan MB . (1994). Mol. Cell. Biol., 14, 1815–1823.
Nicholls CD, McLure KG, Shields MA and Lee PW . (2002). J. Biol. Chem., 277, 12937–12945.
No D, Yao TP and Evans RM . (1996). Proc. Natl. Acad. Sci. USA, 93, 3346–3351.
Nomoto S, Haruki N, Kondo M, Konishi H and Takahashi T . (1998). Cancer Res., 58, 1380–1383.
Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M and Ikawa S . (1998). Nat. Med., 4, 839–843.
Pietenpol JA, Tokino T, Thiagalingam S, el-Deiry WS, Kinzler KW and Vogelstein B . (1994). Proc. Natl. Acad. Sci. USA, 91, 1998–2002.
Robles AI, Bemmels NA, Foraker AB and Harris CC . (2001). Cancer Res., 61, 6660–6664.
Rolley N, Butcher S and Milner J . (1995). Oncogene, 11, 763–770.
Rossi FM and Blau HM . (1998). Curr. Opin. Biotechnol., 9, 451–456.
Saez E, No D, West A and Evans RM . (1997). Curr. Opin. Biotechnol., 8, 608–616.
Sambrook J, Maniatis T and Fritsch EF . (1989). Molecular Cloning: A Laboratory Manual. 2nd edn.. Cold Spring Harbor Laboratory: Cold Spring Harbor, NY.
Saranath D, Khan Z, Tandle AT, Dedhia P, Sharma B, Contractor R, Shrivastava S and Dinshaw K . (2002). Gynecol. Oncol., 86, 157–162.
Sasaki Y, Morimoto I, Ishida S, Yamashita T, Imai K and Tokino T . (2001). Gene Therapy, 8, 1401–1408.
Shinoura N, Muramatsu Y, Asai A, Han S, Horii A, Kirino T and Hamada H . (2000). Cancer Lett., 160, 67–73.
Sifakis S, Basel D, Ianakiev P, Kilpatrick M and Tsipouras P . (2001). Clin. Genet., 60, 165–172.
Soulitzis N, Sourvinos G, Dokianakis DN and Spandidos DA . (2002). Cancer Lett., 179, 175–183.
Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G and Banks L . (1998). Nature, 393, 229–234.
Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, Levine AJ, Sacchi A, Cesareni G, Oren M and Blandino G . (2000). J. Biol. Chem., 275, 29503–29512.
Sunahara M, Ichimiya S, Nimura Y, Takada N, Sakiyama S, Sato Y, Todo S, Adachi W, Amano J and Nakagawara A . (1998). Int. J. Oncol., 13, 319–323.
Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J, Mossner J, Engeland K and Wittekind C . (1999). J. Natl. Cancer Inst., 91, 1154–1158.
Toruner GA, Ucar A, Tez M, Cetinkaya M, Ozen H and Ozcelik T . (2001). Urol. Res., 29, 393–395.
Van Meir EG, Polverini PJ, Chazin VR, Su Huang HJ, de Tribolet N and Cavenee WK . (1994). Nat. Genet., 8, 171–176.
Vogelstein B, Lane D and Levine AJ . (2000). Nature, 408, 307–310.
Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, Hollander MC, O'Connor PM, Fornace Jr AJ and Harris CC . (1999). Proc. Natl. Acad. Sci. USA, 96, 3706–3711.
Wu GS, Burns TF, McDonald III ER, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G and el-Deiry WS . (1997). Nat. Genet., 17, 141–143.
Yang A, Kaghad M, Caput D and McKeon F . (2002). Trends Genet., 18, 90–95.
Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D and McKeon F . (1998). Mol. Cell, 2, 305–316.
Yang A and McKeon F . (2000). Nat. Rev. Mol. Cell Biol., 1, 199–207.
Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C and McKeon F . (1999). Nature, 398, 714–718.
Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F and Caput D . (2000). Nature, 404, 99–103.
Yokomizo A, Mai M, Bostwick DG, Tindall DJ, Qian J, Cheng L, Jenkins RB, Smith DI and Liu W . (1999). Prostate, 39, 94–100.
Zhu J and Chen X . (2000). Mol. Cell. Biol., 20, 5602–5618.
Zhu J, Jiang J, Zhou W and Chen X . (1998). Cancer Res., 58, 5061–5065.
Zhu J, Zhang S, Jiang J and Chen X . (2000). J. Biol. Chem., 275, 39927–39934.
Zhu K, Wang J, Zhu J, Jiang J, Shou J and Chen X . (1999). Oncogene, 18, 7740–7747.
Acknowledgements
We thank S Zhang for technical help in generating HTE20 cell line. This work is supported in part by NCI Grant R01 CA81237.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Willis, A., Pipes, T., Zhu, J. et al. p73 can suppress the proliferation of cells that express mutant p53. Oncogene 22, 5481–5495 (2003). https://doi.org/10.1038/sj.onc.1206505
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206505
Keywords
This article is cited by
-
Silencing E3 Ubiqutin ligase ITCH as a potential therapy to enhance chemotherapy efficacy in p53 mutant neuroblastoma cells
Scientific Reports (2020)
-
Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death
Oncogenesis (2016)
-
KPT-330 has antitumour activity against non-small cell lung cancer
British Journal of Cancer (2014)
-
Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems
Diagnostic Pathology (2012)
-
Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?
Oncogene (2007)